procarbazine - CISMeF

Preferred Label : procarbazine;

MeSH definition : An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.;

CISMeF synonym : procarbazine sigma-tau brand; 366-70-1 (Procarbazine hydrochloride); Sigma-Tau brand of procarbazine; Sigma-Tau brand of procarbazine hydrochloride; cambridge laboratories brand of procarbazine hydrochloride; roche brand of procarbazine hydrochloride; sigma tau brand of procarbazine hydrochloride;

MeSH hyponym : sigma tau brand of procarbazine; matulane; natulan; procarbazine hydrochloride; procarbazine monohydrobromide; Monohydrobromide, Procarbazine; Hydrochloride, Procarbazine; Procarbazine Monohydrochloride; Monohydrochloride, Procarbazine;

MeSH CAS label : benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)-;

MeSH Related Number : procarbazine monohydrobromide; procarbazine hydrochloride; 13309-74-5 (HCl); 18969-59-0 (mono-HBr); 366-70-1 (mono-HCl); 671-16-9 (Procarbazine); XH0NPH5ZX8;

Registry Number MeSH : 671-16-9;

Related CAS MeSH : 18969-59-0 (Procarbazine monohydrobromide); XH0NPH5ZX8 (Procarbazine hydrochloride);

Wikipedia link : https://en.wikipedia.org/wiki/Procarbazine;

Codes EINECS : 211-582-2;

Is substance : O;

UNII : 35S93Y190K;

InChIKey : CPTBDICYNRMXFX-UHFFFAOYSA-N;

Details

Origin ID

D011344;

UMLS CUI

C0033223;

ATC code(s)
- procarbazine [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Matulane [ICD-11 Extension code]
- Matulane [ICHI extension code]
- Procarbazine [ICHI extension code]
CISMeF manual mappings
- Procarbazine adverse reaction (disorder) [SNOMED CT concept]
- Procarbazine poisoning (disorder) [SNOMED CT concept]
- procarbazine [Substance BNPC]
Currated CISMeF NLP mapping
- Procarbazine [ICD-11 Extension code]
- Procarbazine [NCIt concept]
- Procarbazine (substance) [SNOMED CT concept]
- procarbazine [SNOMED Notion]
Pharmacological action(s)
- antineoplastic agents [MeSH Descriptor]
Record concept(s)
- matulane [MeSH concept]
- natulan [MeSH concept]
- procarbazine [MeSH concept]
- procarbazine hydrochloride [MeSH concept]
- procarbazine monohydrobromide [MeSH concept]
Related MeSH Supplementary Concept(s)
- AVN protocol [MeSH Supplementary Concept]
- AVPP protocol [MeSH Supplementary Concept]
- BCPP protocol [MeSH Supplementary Concept]
- BEACOPP protocol [MeSH Supplementary Concept]
- BEMP protocol [MeSH Supplementary Concept]
- BMPD protocol [MeSH Supplementary Concept]
- BOPP protocol [MeSH Supplementary Concept]
- BVCPP protocol [MeSH Supplementary Concept]
- C'MP protocol [MeSH Supplementary Concept]
- CAMP protocol [MeSH Supplementary Concept]
- CAMP-L protocol [MeSH Supplementary Concept]
- CCVPP protocol [MeSH Supplementary Concept]
- CE-AVN protocol [MeSH Supplementary Concept]
- CEP regimen [MeSH Supplementary Concept]
- CEPP protocol [MeSH Supplementary Concept]
- CHIVPP protocol [MeSH Supplementary Concept]
- CHLOROPP protocol [MeSH Supplementary Concept]
- CMOPP protocol [MeSH Supplementary Concept]
- CMPP protocol [MeSH Supplementary Concept]
- CODBLAM IV protocol [MeSH Supplementary Concept]
- COFP protocol 1 [MeSH Supplementary Concept]
- COMP-1 protocol [MeSH Supplementary Concept]
- COMP-VAN protocol [MeSH Supplementary Concept]
- COP-BLAM protocol [MeSH Supplementary Concept]
- COPP protocol [MeSH Supplementary Concept]
- COPP-ABVD protocol [MeSH Supplementary Concept]
- CVPP I protocol [MeSH Supplementary Concept]
- CVPP protocol [MeSH Supplementary Concept]
- CVPP regimen [MeSH Supplementary Concept]
- CVPPABO protocol [MeSH Supplementary Concept]
- ChlVPP protocol [MeSH Supplementary Concept]
- ChlVPP-EVA regimen [MeSH Supplementary Concept]
- DFMO-PCV protocol [MeSH Supplementary Concept]
- DOPP-protocol [MeSH Supplementary Concept]
- DVPP protocol [MeSH Supplementary Concept]
- Dexa-PAMB protocol [MeSH Supplementary Concept]
- ECAPP protocol [MeSH Supplementary Concept]
- EPVP protocol [MeSH Supplementary Concept]
- FONP protocol [MeSH Supplementary Concept]
- LCOMP protocol [MeSH Supplementary Concept]
- LOPP protocol 1 [MeSH Supplementary Concept]
- LOPP protocol 2 [MeSH Supplementary Concept]
- LTPP protocol [MeSH Supplementary Concept]
- MCPP protocol [MeSH Supplementary Concept]
- ML-Y1 protocol [MeSH Supplementary Concept]
- MMPP protocol [MeSH Supplementary Concept]
- MOP protocol [MeSH Supplementary Concept]
- MOP-BAP protocol [MeSH Supplementary Concept]
- MOPP protocol [MeSH Supplementary Concept]
- MOPP-ABV protocol [MeSH Supplementary Concept]
- MOPP-Bleo protocol [MeSH Supplementary Concept]
- MOPPEBVCAD protocol [MeSH Supplementary Concept]
- MPP protocol [MeSH Supplementary Concept]
- MV26PD protocol [MeSH Supplementary Concept]
- MVPF protocol [MeSH Supplementary Concept]
- MVPP protocol [MeSH Supplementary Concept]
- MVPP-Bleo protocol [MeSH Supplementary Concept]
- MVVPP protocol [MeSH Supplementary Concept]
- N-isopropyl-4-formylbenzamide [MeSH Supplementary Concept]
- N-isopropyl-alpha-(2-methylhydrazo)-4-toluamide [MeSH Supplementary Concept]
- NOPP protocol [MeSH Supplementary Concept]
- OEPP protocol [MeSH Supplementary Concept]
- OPP protocol [MeSH Supplementary Concept]
- PAVe protocol 1 [MeSH Supplementary Concept]
- PCAV protocol [MeSH Supplementary Concept]
- PCV protocol [MeSH Supplementary Concept]
- PMV protocol [MeSH Supplementary Concept]
- POCC protocol [MeSH Supplementary Concept]
- PRIME protocol [MeSH Supplementary Concept]
- Pro-MACE-C-MOPP protocol [MeSH Supplementary Concept]
- ProMACE-MOPP protocol [MeSH Supplementary Concept]
- SIOP-II protocol [MeSH Supplementary Concept]
- THP-COPBLM regimen [MeSH Supplementary Concept]
- TPDC-FuHu protocol [MeSH Supplementary Concept]
- TPDCV protocol [MeSH Supplementary Concept]
- VAMP protocol [MeSH Supplementary Concept]
- VAP combination [MeSH Supplementary Concept]
- VAPE protocol [MeSH Supplementary Concept]
- VCDP protocol [MeSH Supplementary Concept]
- VECABOP protocol [MeSH Supplementary Concept]
- VEPEMB protocol [MeSH Supplementary Concept]
- VIPP-BM protocol [MeSH Supplementary Concept]
- VPC protocol [MeSH Supplementary Concept]
- azoprocarbazine [MeSH Supplementary Concept]
- benzylazoxyprocarbazine [MeSH Supplementary Concept]
- methylazoxyprocarbazine [MeSH Supplementary Concept]
- vvp protocol [MeSH Supplementary Concept]
See also inter- (CISMeF)
- Product containing procarbazine (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Procarbazine [ICD-11 Extension code]
- Procarbazine [NCIt concept]
- Procarbazine (substance) [SNOMED CT concept]
- Product containing procarbazine (medicinal product) [SNOMED CT concept]
- procarbazine [ATC Code]
- procarbazine [Substance BNPC]
- procarbazine [SNOMED Notion]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients